TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC 2008. Time (days) 5 10 15 0 050100150200250300350400.

Slides:

Advertisements

Similar presentations

HEARTLINE HSM Genoa Cardiology Meeting

Advertisements

Progress in Oral Anti- Platelet Therapy Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital 1.

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.

Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.

Leadership. Knowledge. Community. USE OF ANTIPLATELET THERAPY IN PATIENTS WITH DIABETES Working Group: Maria E. Wolfs, MD, FRCP; Rémi Rabasa-Lhoret, MD,

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

TOTAL Stroke in the TOTAL trial: Randomized trial of manual aspiration Thrombectomy in STEMI TOTAL Trial Investigators.

TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel TRITON-TIMI 38 TRITON-TIMI 38 Elliott M. Antman, MD.

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.

Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.

ACS is a major public health challenge In the US:  Over 1.5 million people experience ACS annually 1 In the EU:  ACS is the most common cause of death,

Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.

CURE: Prior Stroke or TIA OutcomeC + ASAASAHRP value MI/stroke/ CV death 49/274 (17.9%)52/232 (22.4)0.74 (0.50, 1.10)0.13 Non-CABG TIMI major bleeding.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

The Landscape of Oral Antiplatelet Agents 2009 George D. Dangas, MD, PhD, FSCAI, FACC Associate Professor of Medicine Columbia University Medical Center.

Antiplatelet Options for ACS: The Changing Landscape Dr Harald Vangerow Medical Advisor Cardiovascular Eli Lilly UKEFF00329 Prescribing Information can.

Rob Storey Reader and Honorary Consultant in Cardiology, University of Sheffield The changing world of adjunctive pharmacology.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Evolution of pharmaceutical antithrombotic therapy in CVD Dr Rob Butler Dept of Cardiology University Hospital of North Staffordshire Drug It!

Dr Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield UK Managing bleeding post PCI.

Karlis TRUSINSKIS Interventional Cardiologist Pauls Stradins Clinical University Hospital Riga, LATVIA ANTIAGREGANTS IN ACUTE CORONARY SYNDROME.

What’s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 13.

Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.

EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.

Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.

The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor Results from the TRITON-TIMI 38 Trial.

Reduction in Stent Thrombosis – better tablets or better stents? Dr James Cotton MD FRCP Heart and Lung Centre Wolverhampton.

NSTE Acute Coronary Syndromes

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

TRITON-TIMI 38 AHA 2007 Orlando, Florida

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Adjunctive Antithrombotic for PCI Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville.

Antiplatelet therapy for STEMI: The Case for Clopidogrel

Figure 1 Ischaemic endpoints

LEADER trial: Primary Outcome

PRAGUE-18 Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596). Results (p = 0.94)

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.

The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor

TNT: Baseline and final LDL cholesterol levels

The ANTARCTIC investigators

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Efficacy of Cangrelor vs. Clopidogrel

Table. Clinical Efficacy and Safety

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

ASCOT-BPLA: Primary and secondary end points

BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.

Preventive Angioplasty in Myocardial Infarction Trial

APEX: Primary Efficacy and Safety Results

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

What oral antiplatelet therapy would you choose?

Cystatin C levels and risk of death from all causes

TRITON-TIMI 38 AHA 2007 Orlando, Florida

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

FIELD: Primary outcome

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days) Proportion of patients (%) HR=0.79 (0.65–0.97) NNT=42 P=0.02 RRR=21% P=0.002 RRR=32% Clopidogrel Prasugrel Age-adjusted HR=0.81 ( )

TRITON TIMI-38 STEMI cohort Efficacy End Points at 15 Months Clopidogrel Prasugrel P=0.11 P=0.02 P=0.09 P=0.02 P=0.007 P=0.03 P=0.02 Proportion of population (%) All DeathMIUTVRStent Thrombosis* CV Death/ MI CV Death/ MI/UTVR CV Death/ MI/Stroke * ARC def/probable Adapted from Montalescot et al. ESC 2008.

TRITON TIMI-38 STEMI cohort Stent thrombosis ARC Definite/probable HR=0.58 (0.36–0.93) NNT=83 P=0.02 RRR=42% Proportion of patients (%) Time (Days) P=0.008 RRR=51% Clopidogrel Prasugrel Age-adjusted HR=0.59 ( ) Adapted from Montalescot et al. ESC 2008.

TRITON TIMI-38 STEMI cohort TIMI major non-CABG bleeding HR=1.11 (0.70–1.77) NNH=333 Proportion of patients (%) Time (Days) P= Clopidogrel Prasugrel Age-adjusted HR=1.19 ( ) Adapted from Montalescot et al. ESC 2008.

TRITON TIMI-38 STEMI cohort End point Nondiabetics, HR (95% CI) Diabetics, HR (95% CI) P for interaction CV death, nonfatal MI, or stroke* 0.86 (0.76–0.98) 0.70 (0.58–0.85) 0.09 MI 0.82 (0.72–0.95) 0.60 (0.48–0.76) 0.02 Major hemorrhage 1.43 (1.07–1.91) 1.06 (0.66–1.69) 0.29 Major or minor hemorrhage 1.32 (1.08–1.61) 1.30 (0.92–1.82) 0.93 All-cause death or nonfatal MI, stroke, or major hemorrhage 0.92 (0.82–1.03) 0.74 (0.62–0.89) 0.05 Adapted from Wiviott et al. Circulation 2008; available at: *primary end point Hazard Ratios for Primary and Other End Points, Prasugrel vs. Clopidogrel, for Nondiabetics and Diabetics in TRITON-TIMI 38